Fingolimod Zentiva
Indication :single disease- modifying therapy in highly active relapsing remitting multiple sclerosis for the following groups of adult patients and pediatric patients aged 10 years and older with body weight > 40 kg
− patients with highly active disease despite a full and adequate course of treatment with at least 1 disease modifying therapy or
− patients with rapidly evolving severe relapsing remitting multiple sclerosis defined by 2 or more disabling relapses in 1 year, and with 1 or more Gadolinium enhancing lesions on brain MRI or a significant increase in T2 lesion load as compared to a previous recent MRI.
- EU approved.
- Commercialized in France, UK, Spain
is a patient access and affordability program, aiming to support financially patients living with multiple sclerosis and already treated with (initiated) Fingolimod Zentiva in Lebanon
Several of the multiple sclerosis (MS) therapies in Lebanon come with a high price-tag, and can be difficult to afford to majority of MS patients, from the mid to low affordable segment.
Cureleads is planning to implement a MuSaadeh, aiming to help these patients in addressing affordability challenges, especially in the self-pay segment, by providing eligible patients free of charge packs of Fingolimod Zentiva, according to their specific financial situation to be assessed by a third independent body – Careleads.
The focus is to address affordability problems MS patients experience, following a diagnosis or prescription made by a neurologist, so patient outcomes can be optimized.
Eligible patients must be getting treatment for MS and must reside and receive treatment in Lebanon.
If You are interested:
Contact information of PSP
